Soligenix, Inc. (SNGX)

Soligenix's stock price has significantly declined over the past year, with volatility in the past six months. In September 2025, Soligenix closed a $7.5 million public offering for research and development. In November 2025, the company reported Q3 earnings with an EPS of -$0.58, beating estimates, and achieved an enrollment milestone for HyBryte™'s Phase 3 trial. In December 2025, top-line results of the Phase 2a study of SGX302 were announced, and positive results from the Phase 2 trial of SGX945 were published. In January 2026, Soligenix completed a key Phase 2 psoriasis trial and reached an enrollment milestone in the Phase 3 FLASH2 trial for HyBryte™.

The provided search results do not contain specific information regarding demand seasonality for Soligenix, Inc.'s products and services. Demand for its products is likely driven by medical need and public health initiatives rather than typical seasonal consumer patterns.

Soligenix, Inc. is a late-stage biopharmaceutical company in Princeton, New Jersey, focused on developing and commercializing products for rare diseases with unmet medical needs, operating in the Biotechnology and Pharmaceutical Preparations industry. Its pipeline includes Specialized BioTherapeutics, such as HyBryte™ for cutaneous T-cell lymphoma (CTCL) and SGX942 for inflammatory diseases, and Public Health Solutions, including RiVax® for ricin toxin prevention and CiVax™ for COVID-19 prevention.

Soligenix, Inc. is headquartered in Princeton, New Jersey, United States, focusing on developing and commercializing products for rare diseases in the United States. While primarily focused on the US market, the company will seek regulatory approvals to support potential worldwide commercialization for some products upon successful completion of Phase 3 studies.

Soligenix's brand reputation is driven by its clinical trial progress and scientific publications, including positive results for SGX945 and SGX302, and milestones for HyBryte™. The company is recognized for its focus on rare diseases. However, the stock price decline suggests a disconnect between clinical progress and market perception, impacting investor confidence, with analysts noting puzzlement at the market's subdued response to encouraging clinical results.

Soligenix, Inc. has 28 institutional owners holding 1,415,573 shares, representing 3.60% of the stock, with major holders including Armistice Capital, Llc and DRW Securities, LLC. The general public, mostly retail investors, holds a substantial stake, while insiders own under 1%. Key executives include Dr. Christopher J. Schaber (CEO), Jonathan L. Guarino (CFO), Dr. Richard Straube (CMO), and Dr. Oreola Donini (CSO).